Outlook Therapeutics receives marketing approval from the European Commission for Lytenava (bevacizumab Gamma) for the treatment of wet AMD
Outlook Therapeutics 获得欧盟委员会用于治疗湿性 AMD 的 Lytenava（贝伐珠单抗 Gamma）的上市许可
Outlook Therapeutics receives marketing approval from the European Commission for Lytenava (bevacizumab Gamma) for the treatment of wet AMD
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.